Asahi Kasei regains global rights to thrombomodulin through Artisan buyout
This article was originally published in Scrip
Executive Summary
The pharma division of Japan's Asahi Kasei has bought out the private US venture Artisan Pharma, in which it was already an investor and to which it had licensed the recombinant human thrombomodulin-alfa product ART-123 for development outside Asia.